JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

NCT ID: NCT06045585

Last Updated: 2023-09-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-18
• Study Completion Date: 2025-12-31

Brief Summary

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell lymphoma

Detailed Description

This is a single-center, single-arm, open-treatment clinical study. In this study, approximately 10-20 adult and elderly patients with CD19-positive relapsed or refractory B-cell lymphoma will be enrolled for JY231 infusion therapy. The safety of JY231 was evaluated by observing adverse events after cell therapy. Evaluate the effectiveness of JY231 treatment compared to the results of the subjects' own previous standard treatment regimens or base data. Blood, bone marrow, and cerebrospinal fluid were collected before and 12 months after the JY231 infusion to detection.

Conditions

Relapsed or Refractory B-cell Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

infusion of JY231 injection

Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.

Group Type: EXPERIMENTAL

infusion of JY231 injection

Intervention Type: BIOLOGICAL

Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.

Interventions

infusion of JY231 injection

Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. understand and sign the informed consent and are willing and able to comply with all test requirements;

2. Age 18-75 years old, gender is not limited;

3. Flow cytometry or malignant tumor cells were CD19 positive;

4. Meet the clinical criteria for r/r B-cell lymphoma, including: indolent lymphoma (iNHL), follicular lymphoma (FL) and marginal zone lymphoma (MZL); Invasive B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and T-lymphocyt-rich large B-cell lymphoma (TCRBCL);

5. There is at least one measurable lesion on imaging (Lugano 2014 criteria), that is, a lymph node lesion with a diameter greater than 15 mm on CT cross-sectional images or an extranodal lesion with a diameter greater than 10 mm, with a positive FDG-PET test.

6. Expected survival ≥12 weeks;

7. The ECOG (Eastern Tumor Collaboration Group) score at baseline was 0 ~ 1;

8. Adequate organ function (indicators involving liver and kidney function can be appropriately relaxed) :

• ALT ≤3 xULN;
• AST)≤3x ULN;
• Total bilirubin ≤1.5 x ULN;
• Serum creatinine ≤ 1.5x ULN, or creatinine clearance ≥60 mL/min;
• Indoor oxygen saturation ≥92%;
• Left ventricular ejection fraction (LVEF) ≥55%, echocardiography confirmed no pericardial effusion, no clinically significant ECG findings;
• No clinically significant pleural effusion;

9. Sufficient who with adequate bone marrow reserve, defined as:

Absolute neutrophil count (ANC) > 1.000 /mm3; Absolute lymphocyte count (ALC) ≥300 /mm3; Platelet ≥50.000 /mm3; Hemoglobin > 8.0g/dl;

10. Using the following drugs must meet the following conditions:

• Steroids: Therapeutic doses of steroids must be discontinued 72 hours before JY231 infusion. Physiological replacement doses of steroids are permitted;
• Immunosuppression: Any immunosuppressive drug must be stopped ≥4 weeks prior to enrollment;
• Anti-proliferative therapy other than lympho-depleting chemotherapy within two weeks of infusion; CD20 antibody therapy must be discontinued within 4 weeks prior to infusion or 5 half-lives (whichever is older);
• CNS disease prevention must be stopped 1 week before JY231 infusion (e.g., intrathecal methotrexate).

11. Fertile men, to ensure that sexual partners can effectively prevent contraception; Women who are fertile, use effective birth control and consent to use birth control throughout the study period.

Exclusion Criteria

1. Subjects with active cerebrospinal fluid malignant cells or brain metastases, or subjects with active central nervous system (CNS) lymphoma;

2. Subjects with a history of active CNS disease, such as seizures, cerebrovascular ischemia/bleeding, dementia, cerebellar disease, or any autoimmune disease involving the central nervous system;

3. Subjects who have received other study drugs within 30 days prior to screening;

4. Subjects who have previously received any anti-CD19 / anti-CD3 therapy or any other anti-CD19 therapy (except those with adequate bone marrow reserve and whose tumor is CD19-positive);

5. Patients who have previously been treated with any gene therapy product, including CAR-T therapy (except those with no CAR T in the body, normal T cell count and function, and CD19-positive tumors);

6. Subjects undergoing radiation therapy within 2 weeks prior to infusion;

7. Subjects with active hepatitis B (defined as hepatitis B virus DNA test value > 500 IU/mL) or hepatitis C (HCV RNA positive); Hiv-positive or treponem-positive subjects;

8. Subjects with an acute life-threatening bacterial, viral, or fungal infection that has not yet been controlled (e.g., positive blood culture ≤72 hours prior to infusion);

9. Participants with unstable angina pectoris and/or myocardial infarction in the 6 months prior to screening;

10. Subjects with prior or concurrent development of other malignancies, except in the following cases:

• Adequately treated basal cell, thyroid papillary, squamous cell carcinomas (requiring adequate wound healing prior to enrollment);
• Carcinoma in situ of cervical or breast cancer with curative treatment and no signs of recurrence for at least 3 years prior to the study;
• The primary malignancy has been completely removed and in complete remission for ≥5 years.

11. Clinically significant ventricular arrhythmia;

12. Subjects received anticoagulant therapy within a week;

13. Active neuroautoimmune or inflammatory conditions (e.g. Guillian-Barre syndrome, amyotrophic lateral sclerosis);

14. Pregnant or lactating women, and female subjects who are planning to become pregnant within 2 years after JY231 injection infusion or male subjects whose partners plan to become pregnant within 2 years after JY231 injection infusion;

15. Subjects who, in accordance with the investigator's judgment and/or clinical standards, are contraindicated with any study procedure or have other medical conditions that may place them at unacceptable risk.

16. Other conditions that the investigator believes should not be included in this clinical trial, such as poor compliance.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Guangdong Second Provincial General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Qing Zhang

Chief Physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Qing Zhang, Doctoral

Role: PRINCIPAL_INVESTIGATOR

Guangdong Second Provincial General Hospital

Locations

Guangdong Second Provincial General Hospital

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Qing Zhang, Doctoral

Role: CONTACT

zhqing@vip.163.com

+86 20 8916 8162

References

Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov;12(5):933-41. doi: 10.1016/j.ymthe.2005.04.016. Epub 2005 Jun 23.

Reference Type: BACKGROUND

PMID: 15979412 (View on PubMed)

Frank AM, Weidner T, Brynza J, Uckert W, Buchholz CJ, Hartmann J. CD8-Specific Designed Ankyrin Repeat Proteins Improve Selective Gene Delivery into Human and Primate T Lymphocytes. Hum Gene Ther. 2020 Jun;31(11-12):679-691. doi: 10.1089/hum.2019.248. Epub 2020 Apr 23.

Reference Type: BACKGROUND

PMID: 32160795 (View on PubMed)

Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018 Oct;53:164-181. doi: 10.1016/j.copbio.2018.01.025. Epub 2018 Feb 18.

Reference Type: BACKGROUND

PMID: 29462761 (View on PubMed)

Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Schonfeld K, Schambach A, Wels WS, Kneissl S, Uckert W, Buchholz CJ. T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood. 2012 Nov 22;120(22):4334-42. doi: 10.1182/blood-2012-02-412973. Epub 2012 Aug 16.

Reference Type: BACKGROUND

PMID: 22898597 (View on PubMed)

Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, Bonagofski E, Wohlfahrt ME, Pillai SPS, Stephan MT. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017 Aug;12(8):813-820. doi: 10.1038/nnano.2017.57. Epub 2017 Apr 17.

Reference Type: BACKGROUND

PMID: 28416815 (View on PubMed)

Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015 Jan 23;4(3):e994446. doi: 10.4161/2162402X.2014.994446. eCollection 2015 Mar.

Reference Type: BACKGROUND

PMID: 25949921 (View on PubMed)

Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017 Jan 4;25(1):285-295. doi: 10.1016/j.ymthe.2016.10.020. Epub 2017 Jan 4.

Reference Type: BACKGROUND

PMID: 28129122 (View on PubMed)

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22.

Reference Type: BACKGROUND

PMID: 17242396 (View on PubMed)

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.

Reference Type: BACKGROUND

PMID: 28925994 (View on PubMed)

Other Identifiers

JY-CT-23-002

Identifier Type: -

Identifier Source: org_study_id